Geographic Variation of Benign Lung Disease in the US: Implications for Lung Cancer Screening

2012 ◽  
Vol 22 (9) ◽  
pp. 662
Author(s):  
S.A. Deppen ◽  
S. Phillips ◽  
M.C. Aldrich ◽  
Y. Shyr ◽  
E.L. Grogan
2020 ◽  
Author(s):  
Nils Hoyer ◽  
Laura H. Thomsen ◽  
Mathilde M.W. Wille ◽  
Torgny Wilcke ◽  
Asger Dirksen ◽  
...  

Abstract Background Interstitial lung abnormalities (ILA) are common in participants of lung cancer screening trials and broad population-based cohorts. They are associated with increased mortality, but less is known about disease specific morbidity and healthcare utilisation in individuals with ILA. Methods We included all participants from the screening arm of the Danish Lung Cancer Screening Trial with available baseline CT scan data (n=1990) in this cohort study. The baseline scan was scored for the presence of ILA and patients were followed for up to 12 years. Data about all hospital admissions, primary healthcare visits and medicine prescriptions were collected from the Danish National Health Registries and used to determine the participants’ disease specific morbidity and healthcare utilisation using Cox proportional hazards models. Results The 332 (16.7%) participants with ILA were more likely to be diagnosed with one of several respiratory diseases, including interstitial lung disease (HR: 4.9, 95% CI: 1.8–13.3, p=0.008), COPD (HR: 1.7, 95% CI: 1.2–2.3, p = 0.01), pneumonia (HR: 2.0, 95% CI: 1.4–2.7, p<0.001), lung cancer (HR: 2.7, 95% CI: 1.8–4.0, p<0.001) and respiratory failure (HR: 1.8, 95% CI: 1.1–3.0, p=0.03) compared with participants without ILA. These findings were confirmed by increased hospital admission rates with these diagnoses and more frequent prescriptions for inhalation medicine and antibiotics in participants with ILA. Conclusions Individuals with ILA are more likely to receive a diagnosis and treatment for several respiratory diseases, including interstitial lung disease, COPD, pneumonia, lung cancer and respiratory failure during long-term follow-up.


Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. S23-S24
Author(s):  
H. Balata ◽  
C. Hayton ◽  
P.V. Barber ◽  
R. Duerden ◽  
M. Evison ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S917-S918
Author(s):  
Leah Tuzzio ◽  
Lorella Palazzo ◽  
Sarah Brush ◽  
Kelly Ehrlich ◽  
Melissa Anderson ◽  
...  

Abstract In 2014, the US Preventive Task Force recommended annual lung cancer screening with low dose CT (LDCT) for adults aged 55 to 80 years old with significant smoking history. Although screening reduces lung cancer mortality, the leading cause of cancer mortality in the US, adherence to screening follow-up remains low. In a human-centered design qualitative study, health services researchers and eight adults over 55 years old from Kaiser Permanente Washington who had recently had an LDCT participated in two co-design sessions. We elicited barriers, facilitators and design principles to develop multilevel interventions that aim to improve adherence to ongoing LDCT. In the initial discussion, participants identified four key areas for improvements to adherence: a) reminders for scheduling and appointments, b) knowledge about tests and follow-up, c) convenience in location and scheduling, and d) financial and non-financial incentives. In a second session, participants referenced patient personas and sketched storyboards, a comic strip-like format showing steps in a journey, to describe different ways to help patients return for LDCTs. Through qualitative analysis, we identified ten elements to consider incorporating in multilevel interventions: versatility (e.g., multiple reminder options), social support (e.g., families, peers), individualization (e.g., tailoring to patient needs), feelings (e.g., fear, relief), knowledge (e.g., harms/benefits, expectations), responsibility (e.g., who is accountable for reminders), continuity (e.g., clear pathway to adherence), consistency (e.g., same messages), cadence (e.g., rhythm of messages), and acknowledgment (e.g., recognition of screening completion). Next steps are to incorporate feedback from clinical stakeholders and develop multilevel interventions for further testing.


Author(s):  
Soumya J Niranjan ◽  
William Opoku-Agyeman ◽  
Nathaniel W Carroll ◽  
Amanda Dorsey ◽  
Meghan Tipre ◽  
...  

Author(s):  
S.J. Niranjan ◽  
W. Opoku-Agyeman ◽  
N.W. Carroll ◽  
A.D. Dorsey ◽  
M.L. Baskin ◽  
...  

2018 ◽  
Author(s):  
Gerald W. Staton Jr ◽  
Eugene A Berkowitz ◽  
Adam Bernheim

Cavitary lesions may occur in the setting of pulmonary infection, neoplasm, or vasculitis.  Cystic lung disease must be differentiated from emphysema and is seen in lymphangioleiomyomatosis, Langerhans cell histiocytosis (LCH), and lymphoid interstitial pneumonia (LIP).  Pulmonary nodules are routinely encountered on chest imaging and may be due to benign or malignant etiologies.  There are follow-up algorithms that provide recommendations for solid and sub-solid nodules in certain clinical scenarios.  Nodules characteristics (such as size, morphology, and number [solitary versus multiple]) and patient characteristics (including age, oncology history, and cigarette smoking status) are important to consider in formulating a differential diagnosis and follow-up plan.  Lung cancer screening computed tomography (CT) is now a recommended screening test for high-risk patients who meet certain eligibility requirements, and should be reported according to the Lung Imaging Reporting and Data System (Lung-RADS). This review contains 28 figures, 3 tables and 26 references Keywords: Cavitary Lung Disease, Granulomatosis with Polyangiitis, Cystic Lung Disease, Lymphoid Interstitial Pneumonia, Pulmonary Emphysema, Pulmonary Nodules, Pulmonary Granulomatous Disease, Arteriovenous Malformation, Lung Cancer Screening, Pulmonary Fungal Infection


JAMA ◽  
2021 ◽  
Vol 326 (5) ◽  
pp. 440
Author(s):  
Bryan S. Squires ◽  
Ronald Levitin ◽  
Inga S. Grills

Author(s):  
Aranzazu Campo Ezquibela ◽  
Amaia Merino Hernandez ◽  
Jessica Gonzalez Gutierrez ◽  
Marta Marin Oto ◽  
Ana Belen Alcaide Ocana ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document